RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
BridgeBio Pharma Stock

BridgeBio Pharma Equity 2025

BridgeBio Pharma Equity

-1.47 B USD

Ticker

BBIO

ISIN

US10806X1028

WKN

A2PLX7

In 2025, BridgeBio Pharma's equity was -1.47 B USD, a 8.39% increase from the -1.35 B USD equity in the previous year.

BridgeBio Pharma Aktienanalyse

What does BridgeBio Pharma do?

BridgeBio Pharma Inc. is a US biotech company founded in 2015. The company is based in Palo Alto, California and specializes in researching and developing medications for rare diseases. BridgeBio's business model is based on a pipeline of rare diseases that have little or no existing treatment options. The company identifies, finances, and operates individual independent subsidiary companies with the goal of developing precision medicines for rare and genetic diseases. An important element of BridgeBio's business strategy is strategic collaboration with academic institutions and other companies to share research and development expertise. BridgeBio has various subsidiary companies, each specializing in the development of medications for a specific genetic disease. These include Eidos Therapeutics, QED Therapeutics, PellePharm, Navire Pharma, Origin Biosciences, CoA Therapeutics, Calcilytix Therapeutics, Phoenix Tissue Repair, and MyoKardia. Eidos Therapeutics is constantly searching for therapies for transthyretin-mediated amyloidosis (ATTR), a rare cardiovascular disease caused by the buildup of amyloid proteins in various parts of the body. The first FDA-approved eprodisate therapy became available in Japan in 2005, making Eidos Therapeutics one of the most promising subsidiary companies of BridgeBio. QED Therapeutics specializes in developing therapies for Gorlin syndrome and medulloblastoma, a type of brain tumor. PellePharm aims to develop a topical therapy for Gorlin syndrome that can be used to control and treat tumors and non-tumorous skin changes. Navire Pharma explores specific kinases that influence cell growth and cell death signaling pathways to identify healing methods for cancer patients. Calcilytix Therapeutics focuses on discovering a treatment solution for chronic kidney diseases, with a main focus on stopping or reducing the loss of kidney function. Overall, BridgeBio is dedicated to the development of precision medicines designed to combat the underlying genetic causes of rare diseases. The company also advances the field of precision medicine and works closely with doctors and patients to improve the diagnosis of rare diseases and optimize patient care. In 2019, BridgeBio Pharma announced a strategic partnership with the Pharmaceutical Research and Manufacturers of America (PhRMA). The goal of this collaboration is to improve awareness of rare diseases and create better access to new medications. BridgeBio hopes that the partnership will accelerate the development of therapies for rare diseases. In conclusion, BridgeBio Pharma Inc. is an innovative biotech company specializing in the development of precision medicines for the treatment of rare genetic diseases. With a business model based on collaboration with subsidiary companies and strategic partners, BridgeBio Pharma Inc. aims to revolutionize the treatment and cure of patients with rare genetic diseases. BridgeBio Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing BridgeBio Pharma's Equity

BridgeBio Pharma's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding BridgeBio Pharma's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating BridgeBio Pharma's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

BridgeBio Pharma's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in BridgeBio Pharma’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about BridgeBio Pharma stock

What is the equity of BridgeBio Pharma this year?

BridgeBio Pharma has equity of -1.47 B USD this year.

What was the equity of BridgeBio Pharma compared to the previous year?

The equity of BridgeBio Pharma has increased/decreased by 8.39% increased compared to the previous year.

What impact does a high equity have on investors of BridgeBio Pharma?

A high equity is advantageous for investors of BridgeBio Pharma as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of BridgeBio Pharma?

A low equity can be a risk for investors of BridgeBio Pharma, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of BridgeBio Pharma affect the company?

An increase in equity of BridgeBio Pharma can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of BridgeBio Pharma affect the company?

A reduction in equity of BridgeBio Pharma can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of BridgeBio Pharma?

Some factors that can affect the equity of BridgeBio Pharma include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of BridgeBio Pharma so important for investors?

The equity of BridgeBio Pharma is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can BridgeBio Pharma take to change the equity?

To change equity, BridgeBio Pharma can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does BridgeBio Pharma pay?

Over the past 12 months, BridgeBio Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, BridgeBio Pharma is expected to pay a dividend of 0 USD.

What is the dividend yield of BridgeBio Pharma?

The current dividend yield of BridgeBio Pharma is .

When does BridgeBio Pharma pay dividends?

BridgeBio Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of BridgeBio Pharma?

BridgeBio Pharma paid dividends every year for the past 0 years.

What is the dividend of BridgeBio Pharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is BridgeBio Pharma located?

BridgeBio Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von BridgeBio Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of BridgeBio Pharma from 8/1/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/1/2025.

When did BridgeBio Pharma pay the last dividend?

The last dividend was paid out on 8/1/2025.

What was the dividend of BridgeBio Pharma in the year 2024?

In the year 2024, BridgeBio Pharma distributed 0 USD as dividends.

In which currency does BridgeBio Pharma pay out the dividend?

The dividends of BridgeBio Pharma are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von BridgeBio Pharma

Our stock analysis for BridgeBio Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BridgeBio Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.